Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study Meeting Abstract
| Authors: | Scher, H. I.; Fizazi, K.; Saad, F.; Taplin, M. E.; Sternberg, C. N.; Miller, K.; De Wit, R.; Mulders, P.; Hirmand, M.; Selby, B.; De Bono, J. S.; for the AFFIRM Investigators |
| Abstract Title: | Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study |
| Meeting Title: | 2012 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 5 Suppl. |
| Meeting Dates: | 2012 Feb 2-4 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-02-10 |
| Language: | English |
| ACCESSION: | WOS:000208892400002 |
| DOI: | 10.1200/jco.2012.30.5_suppl.lba1 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract : LBA1 -- Source: Wos |
